Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12496639 | 0.80 | PTK2 (0.32) | PTK2 | |
| SCHEMBL19736688 | 0.75 | KIF11 (0.32) | — | |
| SCHEMBL19736786 | 0.75 | PRMT5 (0.39) | CYP11B2CYP11B1 | |
| SCHEMBL702625 | 0.74 | DCUN1D1 (0.50) | POLB | |
| SCHEMBL22158356 | 0.74 | XDH (0.37) | CYP2A6 | |
| SCHEMBL31357013 | 0.74 | CYP1A1 (0.46) | CYP11B2CYP11B1CHRNB2CHRNA4 | |
| SCHEMBL12480275 | 0.73 | USP2 (0.30) | — | |
| SCHEMBL31357027 | 0.73 | PRMT5 (0.39) | CYP11B2 | |
| SCHEMBL382819 | 0.72 | ATM (0.44) | CYP2A6 | |
| SCHEMBL14392676 | 0.72 | CYP2A6 (0.61) | PTK2CYP2A6CYP11B2CYP11B1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | WOLTERING THOMAS (US) | 2015-12-31 | — | — | US | disclosed |
| EP-2948446-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114532-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-7482456-B2 | antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol | MERCK FROSST CANADA | 2009-01-27 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2006-10-05 | — | — | US | disclosed |
| EP-1635829-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004096220-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | PTK2 2441/4885CYP2A6 75/4885CYP11B2 10/4885 |
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | PTK2 2062/4885CYP2A6 1082/4885CYP11B2 1022/4885 |
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE3B | PTK2 2540/4885CYP2A6 520/4885CYP11B2 451/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | PTK2 2441/4885CYP2A6 75/4885CYP11B2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.